4.4.18 General


8 thoughts on “4.4.18 General”

  1. https://www.nature.com/articles/nature25501

    TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

    Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles, Alessandra Castiglioni, Kobe Yuen, Yulei Wang, Edward E. Kadel III, Hartmut Koeppen, Jillian L. Astarita, Rafael Cubas, Suchit Jhunjhunwala, Romain Banchereau, Yagai Yang, Yinghui Guan, Cecile Chalouni, James Ziai, Yasin Şenbabaoğlu, Stephen Santoro, Daniel Sheinson, Jeffrey Hung, Jennifer M. Giltnane, Andrew A. Pierce, Kathryn Mesh, Steve Lianoglou, Johannes Riegler, Richard A. D. Carano, Pontus Eriksson, Mattias Höglund, Loan Somarriba, Daniel L. Halligan, Michiel S. van der Heijden, Yohann Loriot, Jonathan E. Rosenberg, Lawrence Fong, Ira Mellman, Daniel S. Chen, Marjorie Green, Christina Derleth, Gregg D. Fine, Priti S. Hegde, Richard Bourgon & Thomas Powles

    Genentech and Barts Cancer Institute


  2. Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis

    Mikhail M. Savitski5,’Correspondence information about the author Mikhail M. SavitskiEmail the author Mikhail M. Savitski, Nico Zinn5, Maria Faelth-Savitski5, Daniel Poeckel, Stephan Gade, Isabelle Becher, Marcel Muelbaier, Anne J. Wagner, Katrin Strohmer, Thilo Werner, Stephanie Melchert, Massimo Petretich, Anna Rutkowska, Johanna Vappiani, Holger Franken, Michael Steidel, Gavain M. Sweetman, Omer Gilan, Enid Y.N. Lam, Mark A. Dawson, Rab K. Prinjha, Paola Grandi, Giovanna Bergamini, Marcus Bantscheff



  3. Cell Stem Cell. 2018 Feb 8. pii: S1934-5909(18)30016-X. doi: 10.1016/j.stem.2018.01.016. [Epub ahead of print]
    Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.
    Kooreman NG1, Kim Y2, de Almeida PE3, Termglinchan V3, Diecke S4, Shao NY3, Wei TT3, Yi H2, Dey D3, Nelakanti R3, Brouwer TP1, Paik DT3, Sagiv-Barfi I5, Han A6, Quax PHA7, Hamming JF7, Levy R8, Davis MM9, Wu JC10.
    Author information

    Cancer cells and embryonic tissues share a number of cellular and molecular properties, suggesting that induced pluripotent stem cells (iPSCs) may be harnessed to elicit anti-tumor responses in cancer vaccines. RNA sequencing revealed that human and murine iPSCs express tumor-associated antigens, and we show here a proof of principle for using irradiated iPSCs in autologous anti-tumor vaccines. In a prophylactic setting, iPSC vaccines prevent tumor growth in syngeneic murine breast cancer, mesothelioma, and melanoma models. As an adjuvant, the iPSC vaccine inhibited melanoma recurrence at the resection site and reduced metastatic tumor load, which was associated with fewer Th17 cells and increased CD11b+GR1hi myeloid cells. Adoptive transfer of T cells isolated from vaccine-treated tumor-bearing mice inhibited tumor growth in unvaccinated recipients, indicating that the iPSC vaccine promotes an antigen-specific anti-tumor T cell response. Our data suggest an easy, generalizable strategy for multiple types of cancer that could prove highly valuable in clinical immunotherapy.



Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s